Zydus Cadila has received the final approval from the USFDA to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml.
Clonidine hydrochloride injection is a centrally-acting analgesic solution for use in continuous epidural infusion devices which is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.
The group now has 90 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.
Shares of the company gained Rs 44.60, or 4.69%, to trade at Rs 995.10 at the BSE (Monday).